Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab is a combination therapy regimen being investigated for the treatment of relapsed or refractory soft tissue sarcoma. The regimen consists of a liposomal formulation of irinotecan, which is a topoisomerase I inhibitor designed for enhanced drug delivery and prolonged circulation; temozolomide, an oral alkylating agent that induces DNA damage; and bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis. This Phase 2 study is led by the Second Affiliated Hospital, School of Medicine, Zhejiang University, aiming to evaluate the synergistic efficacy and safety of these agents in patients who have failed prior systemic treatments. The liposomal irinotecan component (specifically the 'Injection (II)' formulation) is a specialized delivery system that improves the therapeutic index of the active metabolite SN-38.
- Other names
- Liposomal Irinotecan + Temozolomide + Bevacizumabirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab-Second Affiliated Hospital, School of Medicine, Zhejiang University-soft tissue sarcoma
02
Targets
Beyond the preview
Go deeper on irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab.